98%
921
2 minutes
20
Hyaluronectin (HN) is a glycoprotein with a high affinity to hyaluronic acid (HA) and known to be a component of the extracellular matrix of tumours. Clinical studies have shown that a low level of HN correlates to tumours with poor prognosis, whereas a high level of HN correlates to tumours with good prognosis. We previously demonstrated in vitro that hyaluronidase activity, which promotes tumour progression and metastatic spread by degradation of HA into angiogenic oligosaccharides, was inhibited or promoted by HN, according to the level of HN-expression. This raises the question of the role played by HN in cancer, and particularly if high and low levels of HN-expression could trigger opposite effects on tumour growth and/or metastatic spread. To address this issue, we used a model of spontaneous lung fluorescent metastases that we characterised previously. We stably transfected the human HN cDNA into fluorescent H460MGFP cells and selected two clones characterised by different levels of HN-expression: HN110 and HN704, with a high and a low level of HN-expression, respectively. In vitro, we demonstrated that HN704 cell migration was significantly increased. Inoculation of clones to nude mice had no significant effect on tumour growth, but clearly revealed opposite effects on metastatic spread: HN110 significantly decreased the number of fluorescent metastases whereas HN704 significantly increased it. We also analysed HN, HA and hyaluronidase contents in sera and tumours. These results demonstrate that HN can play a role as either a suppressor or promoter of metastatic spread.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejca.2006.06.012 | DOI Listing |
ESMO Open
September 2025
Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium. Electronic address:
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), such as abemaciclib and ribociclib, have recently been incorporated as adjuvant strategy in combination with endocrine therapy (ET) for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer at higher risk of recurrence. However, despite a significant reduction in recurrence rates, a subset of patients still experiences distant metastatic spreading, with nearly 10% recurring during or shortly after adjuvant CDK4/6i completion, as observed in pivotal trials. To date, only one small retrospective study has described this emerging population while ongoing trials are not specifically addressing this scenario, leaving both the efficacy of postrelapse treatments and the biological background largely unknown.
View Article and Find Full Text PDFUrol Oncol
September 2025
Cancer Committee of the French Association of Urology (CCAFU), France; Department of Urology, University Hospital of Angers, Angers, France.
Background: Peritoneal recurrence (PREC) following nephrectomy for localized renal cancer (RCC) is rare. Our objective was to report a multicenter analysis of PREC to analyze incidence, treatment, survival and risk factors.
Methods: Between 1987 and 2023, patients with PREC following radical or partial nephrectomy (PN) for localized RCC across ten European institutions (UroCCR, NKI, IRCCS, Foch and Gustave Roussy centers) were included.
Cancer Lett
September 2025
Fox Chase Cancer Center, Protocol Support Laboratory, 333 Cottman Ave., Philadelphia, PA 19111, USA.
Historically, polyploid giant cancer cells (PGCCs) within tumors have been ignored as superfluous inflammatory refuse with no intrinsic clinical or biological relevance. However recently, multiple studies have described the existence PGCCs in solid tumor masses that appear to correlate with tumor progression, and can also appear in blood circulation as cancer associated macrophage like cells (CAMLs). In an effort to understand the clinical and biological role of CAMLs (i.
View Article and Find Full Text PDFNeuron
September 2025
Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address:
It is becoming increasingly clear that the nervous system and cancer execute an intimate crosstalk, influencing cancer initiation, growth, spread, and resistance mechanisms. Cancer, vice versa, can change the nervous system. These mostly harmful neuro-cancer interactions constitute the emerging field of "cancer neuroscience.
View Article and Find Full Text PDFNeuron
September 2025
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia.
Neural signaling regulates multiple steps in the metastatic cascade. In this NeuroView, Sloan and Chang suggest that the neural landscape of metastatic microenvironments is highly dynamic and describe opportunities to target peripheral neuroplasticity for personalized anti-metastatic therapeutic interventions.
View Article and Find Full Text PDF